Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: Equivalent efficacy with a lower concentration and more convenient dosing schedule

Cutis

Volumn 74, Issue 6 SUPPL., 2004, Pages 18-23

  Jorizzo, Joseph L ^a,j   Carney, Patrick S ^b,c,d,k   Ko, William T ^e,k   Robins, Perry ^f,k   Weinkle, Susan H ^g,l   Werschler, Wm Philip ^h,i,m  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Advancements in Dermatology   (United States)

^d SkinSpeaks Spa MD   (United States)

^e Arizona Skin and Laser Ther Inst   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g Spokane Dermatology Clinic ^*

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ Spokane Dermatology Clinic   (United States)

^j 3M COMPANY   (United States)

^k Dermik Laboratories   (United States)

^l Galderma Laboratories   (United States)

^m Valeant Pharmaceuticals International   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MICROSPHERE;

ACTINIC KERATOSIS; ARTICLE; BURNING SENSATION; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; CREAM; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG USE; ECONOMIC ASPECT; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HEMOCONCENTRATION; HUMAN; HYPERPIGMENTATION; PAIN; PHOTOSENSITIVITY; PRESCRIPTION; PRURITUS; RISK ASSESSMENT; SCAR FORMATION; SKIN ALLERGY; SKIN IRRITATION; SKIN ULCER;

ADMINISTRATION, CUTANEOUS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; FLUOROURACIL; HUMANS; KERATOSIS; PHOTOSENSITIVITY DISORDERS; THERAPEUTIC EQUIVALENCY;

EID: 12344296945     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis. 2002;70(suppl 2):4-7.
2. Efudex [packet insert]. Costa Mesa, Calif: Valeant Pharmaceuticals; 2000.
3. Gupta AK, Weiss JS, Jorizzo JL. 5-Fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett. 2001;6:1-6.
4. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70(suppl 2):30-36.
5. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907.
6. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of the 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908-920.
7. Levy S, Furst K, Chern W. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Cutis. 2002;70(suppl 2):14-21.
8. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
9. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:175-181.
10. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
11. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006-2011.
12. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13:575-588.
13. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339.
14. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol. 1991;25:665-667.
15. Robins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol. 2002;1:25-30.
16. Labandeira J, Pereiro M Jr, Valdes F, et al. Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg. 2004;30:517-520.
17. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol. 1976;122:1256-1258.
18. Jorizzo J. How to use interval therapy for comprehensive AK management. Pract Dermatol. 2004;1(suppl):12-15.
19. Carney PS. Understanding new options for AKs: from the lab to the clinic. Pract Dermatol. 2004;1:8-11.